A Novel Tetramethylpyrazine Chalcone Hybrid- HCTMPPK, as a Potential Anti-Lung Cancer Agent by Downregulating MELK

References

• Salehi-Rad R, Li R, Paul MK, Dubinett SM, Liu B. The biology of lung cancer: development of more effective methods for prevention, diagnosis, and treatment. Clin Chest Med. 2020;41(1):25–38. doi:10.1016/j.ccm.2019.10.003
   PubMed Web of Science ®Google Scholar
• Rafei H, El-Bahesh E, Finianos A, Nassereddine S, Tabbara I. Immune-based therapies for non-small cell lung cancer. Anticancer Res. 2017;37(2):377–387. doi:10.21873/anticanres.11330
   PubMed Web of Science ®Google Scholar
• Lu T, Yang X, Huang Y, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019;11:943–953. doi:10.2147/cmar.S187317
   PubMed Web of Science ®Google Scholar
• Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun. 2022;42(10):937–970. doi:10.1002/cac2.12359
   PubMed Web of Science ®Google Scholar
• Nagasaka M, Gadgeel SM. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Rev Anticancer Ther. 2018;18(1):63–70. doi:10.1080/14737140.2018.1409624
   PubMed Web of Science ®Google Scholar
• Pirker R. Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer. Curr Opin Oncol. 2020;32(1):63–67. doi:10.1097/cco.0000000000000592
   PubMed Web of Science ®Google Scholar
• Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Current diagnosis and management of small-cell lung cancer. Mayo Clin Proc. 2019;94(8):1599–1622. doi:10.1016/j.mayocp.2019.01.034
   PubMed Web of Science ®Google Scholar
• Constantinescu T, Lungu CN. Anticancer activity of natural and synthetic chalcones. Int J Mol Sci. 2021;22(21):11306.
   PubMed Web of Science ®Google Scholar
• Zhai B, Zhang N, Han X, et al. Molecular targets of β-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: a review. Biomed Pharmacother. 2019;114:108812. doi:10.1016/j.biopha.2019.108812
   PubMed Web of Science ®Google Scholar
• Yang A-Y, Liu H-L, Yang Y-F. Study on the mechanism of action of Scutellaria barbata on hepatocellular carcinoma based on network pharmacology and bioinformatics. Front Pharmacol. 2022;13:1072547. doi:10.3389/fphar.2022.1072547
   PubMed Web of Science ®Google Scholar
• Luo H, Vong CT, Chen H, et al. Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine. Chin Med. 2019;14:48. doi:10.1186/s13020-019-0270-9
   PubMed Web of Science ®Google Scholar
• Ouyang Y, Li J, Chen X, Fu X, Sun S, Wu Q. Chalcone derivatives: role in anticancer therapy. Biomolecules. 2021;11(6):894.
   PubMed Web of Science ®Google Scholar
• Dong Y, Yang Y, Wei Y, Gao Y, Jiang W, Wang G. Ligustrazine eases lung cancer by regulating PTEN and Wnt/β-catenin pathway. Transl Cancer Res. 2020;9(3):1742–1751. doi:10.21037/tcr.2020.03.26
   PubMed Web of Science ®Google Scholar
• Ma X, Ruan Q, Ji X, Yang J, Peng H. Ligustrazine alleviates cyclophosphamide-induced hepatotoxicity via the inhibition of Txnip/Trx/NF-κB pathway. Life Sci. 2021;274:119331. doi:10.1016/j.lfs.2021.119331
   PubMed Web of Science ®Google Scholar
• Zou Y, Zhao D, Yan C, et al. Correction to novel ligustrazine-based analogs of piperlongumine potently suppress proliferation and metastasis of colorectal cancer cells in vitro and in vivo. J Med Chem. 2020;63(2):880–881. doi:10.1021/acs.jmedchem.9b02072
   PubMed Web of Science ®Google Scholar
• Qian J, Xu Z, Zhu P, et al. A derivative of piperlongumine and ligustrazine as a potential thioredoxin reductase inhibitor in drug-resistant hepatocellular carcinoma. J Nat Prod. 2021;84(12):3161–3168. doi:10.1021/acs.jnatprod.1c00618
   PubMed Web of Science ®Google Scholar
• Liu YL, Yan ZX, Xia Y, et al. Ligustrazine reverts anthracycline chemotherapy resistance of human breast cancer by inhibiting JAK2/STAT3 signaling and decreasing fibrinogen gamma chain (FGG) expression. Am J Cancer Res. 2020;10(3):939–952.
   PubMed Web of Science ®Google Scholar
• Gao F, Huang G, Xiao J. Chalcone hybrids as potential anticancer agents: current development, mechanism of action, and structure-activity relationship. Med Res Rev. 2020;40(5):2049–2084. doi:10.1002/med.21698
   PubMed Web of Science ®Google Scholar
• Luo Y, Wu W, Zha D, et al. Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents. Bioorg Med Chem Lett. 2021;47:128230. doi:10.1016/j.bmcl.2021.128230
   PubMed Web of Science ®Google Scholar
• Feng LS, Xu Z, Chang L, et al. Hybrid molecules with potential in vitro antiplasmodial and in vivo antimalarial activity against drug-resistant Plasmodium falciparum. Med Res Rev. 2020;40(3):931–971. doi:10.1002/med.21643
   PubMed Web of Science ®Google Scholar
• Li Z, Yulei J, Yaqing J, et al. Protective effects of tetramethylpyrazine analogue Z-11 on cerebral ischemia reperfusion injury. Eur J Pharmacol. 2019;844:156–164. doi:10.1016/j.ejphar.2018.11.031
   PubMed Web of Science ®Google Scholar
• Das A, Prajapati A, Karna A, et al. Structure-based virtual screening of chemical libraries as potential MELK inhibitors and their therapeutic evaluation against breast cancer. Chem Biol Interact. 2023;376:110443. doi:10.1016/j.cbi.2023.110443
   PubMed Web of Science ®Google Scholar
• Ye J, Deng W, Zhong Y, et al. MELK predicts poor prognosis and promotes metastasis in esophageal squamous cell carcinoma via activating the NF‑κB pathway. Int J Oncol. 2022;61(2):1–5.
   Web of Science ®Google Scholar
• Mahasenan KV, Li C. Novel inhibitor discovery through virtual screening against multiple protein conformations generated via ligand-directed modeling: a maternal embryonic leucine zipper kinase example. J Chem Inf Model. 2012;52(5):1345–1355. doi:10.1021/ci300040c
   PubMed Web of Science ®Google Scholar
• Yang H, Zhou H, Wang G, et al. MELK is a prognostic biomarker and correlated with immune infiltration in glioma. Front Neurol. 2022;13:977180. doi:10.3389/fneur.2022.977180
   PubMed Web of Science ®Google Scholar
• Tang BF, Yan RC, Wang SW, Zeng ZC, Du SS. Maternal embryonic leucine zipper kinase in tumor cells and tumor microenvironment: an emerging player and promising therapeutic opportunity. Cancer Lett. 2023;560:216126. doi:10.1016/j.canlet.2023.216126
   PubMed Web of Science ®Google Scholar
• Wang Z, Castro N, Bernstein AM, Wolosin JM. TGFβ1-driven SMAD2/3 phosphorylation and myofibroblast emergence are fully dependent on the TGFβ1 pre-activation of MAPKs and controlled by maternal leucine zipper kinase. Cell Signal. 2024;113:110963. doi:10.1016/j.cellsig.2023.110963
   PubMed Web of Science ®Google Scholar
• Nakano I, Paucar AA, Bajpai R, et al. Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. J Cell Biol. 2005;170(3):413–427. doi:10.1083/jcb.200412115
   PubMed Web of Science ®Google Scholar
• Hu Z, Li L, Li M, et al. miR-21-5p inhibits ferroptosis in hepatocellular carcinoma cells by regulating the AKT/mTOR signaling pathway through MELK. J Immunol Res. 2023;2023:8929525. doi:10.1155/2023/8929525
   PubMed Web of Science ®Google Scholar
• Tang Q, Li W, Zheng X, et al. MELK is an oncogenic kinase essential for metastasis, mitotic progression, and programmed death in lung carcinoma. Signal Transduct Target Ther. 2020;5(1):279. doi:10.1038/s41392-020-00288-3
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.1239303
   PubMed Web of Science ®Google Scholar
• Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11. doi:10.1186/1752-0509-8-s4-s11
   PubMed Web of Science ®Google Scholar
• Dong D, Xu Z, Zhong W, Peng S. Parallelization of molecular docking: a review. Curr Top Med Chem. 2018;18(12):1015–1028. doi:10.2174/1568026618666180821145215
   PubMed Web of Science ®Google Scholar
• Guney E, Menche J, Vidal M, Barábasi AL. Network-based in silico drug efficacy screening. Nat Commun. 2016;7:10331. doi:10.1038/ncomms10331
   PubMed Web of Science ®Google Scholar
• Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther. 2020;206:107447. doi:10.1016/j.pharmthera.2019.107447
   PubMed Web of Science ®Google Scholar
• Jiang R, Xu J, Zhang Y, et al. Ligustrazine alleviates psoriasis-like inflammation through inhibiting TRAF6/c-JUN/NFκB signaling pathway in keratinocyte. Biomed Pharmacother. 2022;150:113010. doi:10.1016/j.biopha.2022.113010
   PubMed Web of Science ®Google Scholar
• Huang HH, Liu FB, Ruan Z, Zheng J, Su YJ, Wang J. Tetramethylpyrazine (TMPZ) triggers S-phase arrest and mitochondria-dependent apoptosis in lung cancer cells. Neoplasma. 2018;65(3):367–375. doi:10.4149/neo_2018_170112N26
   PubMed Web of Science ®Google Scholar
• Yang S, Wu S, Dai W, et al. Tetramethylpyrazine: a review of its antitumor potential and mechanisms. Front Pharmacol. 2021;12:764331. doi:10.3389/fphar.2021.764331
   PubMed Web of Science ®Google Scholar
• Lu HY, Zu YX, Jiang XW, et al. Novel ADAM-17 inhibitor ZLDI-8 inhibits the proliferation and metastasis of chemo-resistant non-small-cell lung cancer by reversing Notch and epithelial mesenchymal transition in vitro and in vivo. Pharmacol Res. 2019;148:104406. doi:10.1016/j.phrs.2019.104406
   PubMed Web of Science ®Google Scholar
• Gielecińska A, Kciuk M, Yahya EB, Ainane T, Mujwar S, Kontek R. Apoptosis, necroptosis, and pyroptosis as alternative cell death pathways induced by chemotherapeutic agents? Biochim Biophys Acta Rev Cancer. 2023;1878(6):189024. doi:10.1016/j.bbcan.2023.189024
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang W, Cheng Y, et al. Design, synthesis and biological evaluation of ligustrazine-flavonoid derivatives as potential anti-tumor agents. Molecules. 2018;23(9):2187.
   PubMed Web of Science ®Google Scholar
• Moradipour A, Dariushnejad H, Ahmadizadeh C, Lashgarian HE. Dietary flavonoid carvacrol triggers the apoptosis of human breast cancer MCF-7 cells via the p53/Bax/Bcl-2 axis. Med Oncol. 2022;40(1):46. doi:10.1007/s12032-022-01918-2
   PubMed Web of Science ®Google Scholar
• Kramer N, Walzl A, Unger C, et al. In vitro cell migration and invasion assays. Mutat Res. 2013;752(1):10–24. doi:10.1016/j.mrrev.2012.08.001
   PubMed Web of Science ®Google Scholar
• Rajasinghe LD, Pindiprolu RH, Gupta SV. Delta-tocotrienol inhibits non-small-cell lung cancer cell invasion via the inhibition of NF-κB, uPA activator, and MMP-9. Onco Targets Ther. 2018;11:4301–4314. doi:10.2147/ott.S160163
   PubMed Web of Science ®Google Scholar
• Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings. J Chem Inf Model. 2021;61(8):3891–3898. doi:10.1021/acs.jcim.1c00203
   PubMed Web of Science ®Google Scholar
• Badouel C, Chartrain I, Blot J, Tassan JP. Maternal embryonic leucine zipper kinase is stabilized in mitosis by phosphorylation and is partially degraded upon mitotic exit. Exp Cell Res. 2010;316(13):2166–2173. doi:10.1016/j.yexcr.2010.04.019
   PubMed Web of Science ®Google Scholar
• Janostiak R, Rauniyar N, Lam TT, et al. MELK promotes melanoma growth by stimulating the NF-κB pathway. Cell Rep. 2017;21(10):2829–2841. doi:10.1016/j.celrep.2017.11.033
   PubMed Web of Science ®Google Scholar
• Xu Q, Ge Q, Zhou Y, et al. MELK promotes Endometrial carcinoma progression via activating mTOR signaling pathway. EBioMedicine. 2020;51:102609. doi:10.1016/j.ebiom.2019.102609
   PubMed Web of Science ®Google Scholar